{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:02:43Z","timestamp":1787580163296,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clml.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T02:08:42Z","timestamp":1680314922000},"page":"505-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-503X","authenticated-orcid":false,"given":"Hayley","family":"Beer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Taylor-Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinir","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.03.008_bib0001","unstructured":"Myeloma Australia. What is myeloma victoria: Myeloma Foundation of Australia; 2017 Available at: https:\/\/myeloma.org.au\/what-is-myeloma\/. Accessed May 16, 2022."},{"key":"10.1016\/j.clml.2023.03.008_bib0002","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/17474086.2015.1021772","article-title":"Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations","volume":"8","author":"Maes","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2023.03.008_bib0003","unstructured":"Australian Institute of Health and Welfare. Cancer data in Australia Canberra: Australian Institute of Health and Welfare; 2021 Available at: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia. Accessed May 16, 2022."},{"key":"10.1016\/j.clml.2023.03.008_bib0004","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17474086.2019.1613886","article-title":"Quality of life in multiple myeloma: considerations and recommendations","volume":"12","author":"Seitzler","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2023.03.008_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.008_bib0006","series-title":"Seminars in Oncology Nursing","article-title":"Patient Reported Outcomes In Optimizing Myeloma Patients\u2019 Health-Related Quality Of Life","year":"2017"},{"key":"10.1016\/j.clml.2023.03.008_bib0007","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3324\/haematol.2015.127860","article-title":"Health-related quality of life in patients with multiple myeloma-does it matter?","volume":"100","author":"Kvam","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.03.008_bib0008","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/hex.13254","article-title":"Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues","volume":"24","author":"Churruca","year":"2021","journal-title":"Health Expect"},{"key":"10.1016\/j.clml.2023.03.008_bib0009","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","article-title":"Patient-reported outcomes in randomized controlled trials of patients with multiple myeloma: a systematic literature review of studies published between 2014 and 2021","volume":"22","author":"Efficace","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.008_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2023.03.008_bib0011","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2023.03.008_bib0012","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2023.03.008_bib0013","series-title":"Reducing Research Waste In (Health-Related) Quality Of Life Research","first-page":"1","article-title":"Introduction To The Special Section","author":"Rutherford","year":"2022"},{"key":"10.1016\/j.clml.2023.03.008_bib0014","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2023.03.008_bib0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2023.03.008_bib0016","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/intqhc\/mzl034","article-title":"A multi-dimensional model of clinical utility","volume":"18","author":"Smart","year":"2006","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.clml.2023.03.008_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2007.11.006","article-title":"STROBE\u2014a checklist to strengthen the reporting of observational studies in epidemiology","volume":"61","author":"Knottnerus","year":"2008","journal-title":"J clin epidemiol"},{"key":"10.1016\/j.clml.2023.03.008_bib0018","first-page":"4184","article-title":"Development of the functional assessment of cancer therapy-multiple myeloma (FACT-MM) scale and validation in the eastern cooperative oncology group trial E1A05","volume":"118","author":"Weiss","year":"2011","journal-title":"Am Soc Hematol"},{"key":"10.1016\/j.clml.2023.03.008_bib0019","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.03.008_bib0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clml.2023.03.008_bib0021","series-title":"Supportive care needs survey: a guide to administration, scoring and analysis","author":"McElduff","year":"2004"},{"key":"10.1016\/j.clml.2023.03.008_bib0022","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2023.03.008_bib0023","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: The COST measure","volume":"120","author":"De Souza","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.03.008_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1261-6","article-title":"Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the myeloma patient outcome scale (MyPOS)","volume":"15","author":"Osborne","year":"2015","journal-title":"BMC cancer"},{"key":"10.1016\/j.clml.2023.03.008_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Info"},{"key":"10.1016\/j.clml.2023.03.008_bib0026","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1049732317697102","article-title":"A guide to field notes for qualitative research: context and conversation","volume":"28","author":"Phillippi","year":"2018","journal-title":"Qual Health Res"},{"key":"10.1016\/j.clml.2023.03.008_bib0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.afjem.2017.08.001","article-title":"A hands-on guide to doing content analysis","volume":"7","author":"Erlingsson","year":"2017","journal-title":"Afr J Emerg Med"},{"key":"10.1016\/j.clml.2023.03.008_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-496","article-title":"Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life","volume":"14","author":"Osborne","year":"2014","journal-title":"Bmc Cancer"},{"key":"10.1016\/j.clml.2023.03.008_bib0029","first-page":"29","article-title":"How people with myeloma perceive patient-reported outcome measures","volume":"20","author":"Galinsky","year":"2021","journal-title":"Canc Nurs Pract"},{"key":"10.1016\/j.clml.2023.03.008_bib0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clml.2023.03.008_bib0031","first-page":"e1603","article-title":"The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies","volume":"18","author":"Crawford","year":"2022","journal-title":"Cancer Rep"},{"key":"10.1016\/j.clml.2023.03.008_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC canc"},{"key":"10.1016\/j.clml.2023.03.008_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2374373517715011","article-title":"Living with multiple myeloma: a focus group study of unmet needs and preferences for survivorship care","volume":"5","author":"Monterosso","year":"2018","journal-title":"J Patient Exp"},{"key":"10.1016\/j.clml.2023.03.008_bib0034","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s12185-018-2516-1","article-title":"Clinical significance of cancer-related fatigue in multiple myeloma patients","volume":"108","author":"Suzuki","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2023.03.008_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ejh.12876","article-title":"Economic burden of relapsed or refractory multiple myeloma: results from an international trial","volume":"99","author":"Robinson","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.03.008_bib0036","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/S2352-3026(15)00192-1","article-title":"The overlooked COST of multiple myeloma","volume":"2","author":"de Souza","year":"2015","journal-title":"The Lancet Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:37Z","timestamp":1761871297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2152265023000903"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Listening to What Matters Most: Consumer Endorsed Patient Reported Outcome Measures (PROMs) for Use in Multiple Myeloma Clinical Trials: A Descriptive Exploratory Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}